Stemline Therapeutics Inc. (NASDAQ:STML)’s share price traded up 1.8% during mid-day trading on Wednesday . The company traded as high as $7.48 and last traded at $7.36, with a volume of 58,740 shares traded. The stock had previously closed at $7.23.

STML has been the topic of several research analyst reports. Roth Capital restated a “buy” rating and set a $32.00 target price on shares of Stemline Therapeutics in a research note on Thursday, June 9th. Jefferies Group restated a “buy” rating and set a $23.00 target price on shares of Stemline Therapeutics in a research note on Monday, June 6th. Wedbush restated an “outperform” rating and set a $16.00 target price on shares of Stemline Therapeutics in a research note on Tuesday, June 7th. Finally, Zacks Investment Research cut shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Stemline Therapeutics currently has a consensus rating of “Buy” and an average target price of $19.56.

The stock’s market capitalization is $130.66 million. The stock has a 50 day moving average of $7.22 and a 200-day moving average of $6.05.

Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.03. On average, equities research analysts predict that Stemline Therapeutics Inc. will post ($2.11) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Stemline Therapeutics stock. Royce & Associates LLC raised its position in Stemline Therapeutics Inc. (NASDAQ:STML) by 318.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 159,179 shares of the biopharmaceutical company’s stock after buying an additional 121,179 shares during the period. Royce & Associates LLC owned about 0.91% of Stemline Therapeutics worth $1,004,000 as of its most recent SEC filing.

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.